Cargando…
Reactive Cutaneous Capillary Endothelial Proliferation Caused by Camrelizumab: Sixteen Case Reports
To investigate the regularity and characteristics of adverse drug reaction (ADR) of reactive cutaneous capillary endothelial proliferation caused by Camrelizumab, so as to provide reference for clinical rational use of drugs. Searching for case reports of Camrelizumab-induced reactive cutaneous capi...
Autores principales: | Hui-Mei, Pang, Guang-Ming, Huang, Xiao-Ling, Qin, Hong-Liang, Zhang, Si-Jun, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389131/ https://www.ncbi.nlm.nih.gov/pubmed/37529461 http://dx.doi.org/10.4103/ijd.ijd_343_22 |
Ejemplares similares
-
Thalidomide for prevention of camrelizumab‐induced reactive cutaneous capillary endothelial proliferation
por: Song, Geng, et al.
Publicado: (2022) -
Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report
por: Wu, Rui, et al.
Publicado: (2022) -
Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation
por: Yin, Liang, et al.
Publicado: (2022) -
Reactive cutaneous capillary endothelial proliferation predicted the efficacy of camrelizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma
por: Ding, Qi, et al.
Publicado: (2023) -
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial
por: Wang, Feng, et al.
Publicado: (2020)